Claims for Patent: 6,916,478

Summary for Patent: 6,916,478

Title:	Vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
Abstract:	The invention relates to novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, methods for preparing same, and their use in the prevention and treatment of infectious diseases.
Inventor(s):	Kadurugamuwa; Jagath L. (Verona, NJ), Beveridge; Terry J. (Elora, CA)
Assignee:	University of Guelph (Ontario, CA)
Application Number:	10/236,557
Patent Claims:	1. An avirulent or attenuated bacterial cell composition comprising a membrane vesicle of a microorganism integrated into a cell surface of the bacterial cell, the membrane vesicle comprising a bilayer and an antigen associated with a surface of the membrane vesicle, wherein the amount of antigen is sufficient to trigger antibody production and wherein the antigen is derived from tbe same microorganism as the membrane vesicle. 2. The composition according to claim 1 wherein the microorganism is a microorganism, which produces natural membrane vesicles. 3. The composition according to claim 1 wherein the microorganism is selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli, Salmonella gastroenteritis (typhimurium), Salmonella typhi, Salmonella enteriditis, Shigella flexneri, Shigella sonnie, Shigella dysenteriae, Neisseria gonorrhoeae, Neisseria meningitides, Haemophilus influenzae, Haemophilus pleuropneumoniae, Pasteurella haemolytica, Pasteurella multilocida, Legionella pneumophila, Treponema pallidum, Tregonema denticola, Treponema orale, Borrelia burgdorferi, Borrelia spp. Leptospira interrogans, Kiebsiella pneumoniae, Proteus vulgaris, Proteus morganii, Proteus mirabilis, Rickettsia prowazeki, Rickettsia typhi, Rickettsia richettsii, Porphyromonas (Bacteriodes) gingivalis, Chlamydia psittaci, Chlamydia pneumoniae, Chlamydia trachomatis, Campylobacter jejuni, Campylobacter intermedis, Camplobacter fetus, Heilcobacter pylori, Francisella tularenisis, Vibrio cholerae, Vibrio parahaemolyticus, Bordetella pertussis, Burkholderie pseudomallei, Brucella abortus, Brucella susi, Brucella melitensis, Brucella canis, Spirillum minus, Pseudomonas mallei, Aeromonas hydrophila, Aeromanas salmonicida, and Yersinia pestis. 4. The composition according to claim 3 wherein the microorganism is selected from the group consisting of Pseudomonas aeruginosa, Shigella flexneri, Shigella dysenteriae, Escherichia coli, Salmonella typhi, and Neisseria gonorrhoeae. 5. The composition according to claim 1, wherein the membrane vesicle has a diameter of about 10 to about 200 nm, which is obtained by treating the microorganism with a surface-active agent, and is characterized by containing outer membrane, cytoplasmic membrane or plasma membrane, and cytoplasm components. 6. The composition according to claim 1 further comprising a second avirulent or attenuated bacterial cell having a second membrane vesicle of a second microorganism integrated into the cell surface of the second bacterial cell, the second membrane vesicle comprising a bilayer and an antigen associated with a surface of the second membrane vesicle, wherein the amount of antigen is sufficient to trigger antibody production in the second bacterial cell and wherein the antigen associated with a surface of the second membrane vesicle is derived from the same microorganism as the second membrane vesicle. 7. A composition according to claim 1 wherein the bactenal cell is selected from the group consisting of Shigella, Salmonella, Vibrio, and Escherichia cells. 8. The composition according to claim 7 wherein the bacterial cell is a Salmonella typhi Ty21a or a Salmonella typhimurium cell. 9. An avirulent or attenuated bacterial cell composition having a membrane vesicle integrated into a surface of the bacterial cell, the membrane vesicle having a bilayer and being derived from a pathogenic bacteria, wherein integration of the membrane vesicle with the surface of the bacterial cell provides antigenic factors produced by the pathogenic bacteria to the surface of the bacterial cell. 10. A method of producing a composition according to claim 9 comprising: (a) incubating the avirulent or attenuated bacterial cell with the membrane vesicle derived from a pathogenic bacteria; and (b) selecting a bacterial cell having a membrane vesicle integrated into a surface of the bacterial cell.

Details for Patent 6,916,478

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Travel Health, Inc.	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	12/15/1989		2015-08-04